Fertility Preservation Clinical Trial
Official title:
Vitrification of In Vitro Matured Oocytes Following the CAPA-IVM Methodology
NCT number | NCT06157619 |
Other study ID # | SIDISI 23001 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | December 2023 |
Est. completion date | March 2025 |
It has been reported that the potential of In Vitro matured oocytes might be affected by the vitrification process. In fact, the freezing and thawing procedures routinely used in IVF laboratories, have not yet been adapted to oocytes coming from early antral follicles (normally used for In Vitro Maturation). This study aims to compare 2 existing protocols for the Vitrification of In Vitro matured oocytes.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | March 2025 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 20 Years to 37 Years |
Eligibility | Inclusion Criteria: Either - Patients with Polycystic ovary morphology: At least 25 follicles (2-9 mm) throughout the ovary and/or increased ovarian volume (>10ml) (it is enough for 1 ovary to meet these criteria) - Patients with good ovarian reserve: High antral follicle count (AFC): = 20 antral follicles in both ovaries or Anti-müllerian hormone (AMH) value =3.5 ng/ml In both cases, without significant uterine or ovarian anomalies Exclusion Criteria: - There are contraindications for the administration of gonadotropins, oral contraceptives and/or other drugs used in the framework of the present study. - Preimplantation Genetic Testing (PGT) Cycles - Oocyte donation cycles - Medical contraindication for pregnancy. - High grade endometriosis (> grade 2) - Cases with extremely poor sperm |
Country | Name | City | State |
---|---|---|---|
Peru | Centro de Fertilidad y Reproducción Asistida | Lima |
Lead Sponsor | Collaborator |
---|---|
Centro de Fertilidad y Reproducción Asistida, Peru | Centro de Estudios e Investigaciones en Biología y Medicina Reproductiva |
Peru,
Braam SC, Ho VNA, Pham TD, Mol BW, van Wely M, Vuong LN. In-vitro maturation versus IVF: a cost-effectiveness analysis. Reprod Biomed Online. 2021 Jan;42(1):143-149. doi: 10.1016/j.rbmo.2020.09.022. Epub 2020 Sep 28. — View Citation
Coello A, Campos P, Remohi J, Meseguer M, Cobo A. A combination of hydroxypropyl cellulose and trehalose as supplementation for vitrification of human oocytes: a retrospective cohort study. J Assist Reprod Genet. 2016 Mar;33(3):413-421. doi: 10.1007/s10815-015-0633-9. Epub 2016 Jan 11. — View Citation
Cohen Y, St-Onge-St-Hilaire A, Tannus S, Younes G, Dahan MH, Buckett W, Son WY. Decreased pregnancy and live birth rates after vitrification of in vitro matured oocytes. J Assist Reprod Genet. 2018 Sep;35(9):1683-1689. doi: 10.1007/s10815-018-1216-3. Epub 2018 Jun 4. — View Citation
Erratum. JCO Glob Oncol. 2022 Mar;8:e2100412. doi: 10.1200/GO.21.00412. No abstract available. — View Citation
Salama M, Ataman L, Taha T, Azmy O, Braham M, Douik F, Khrouf M, Rodrigues JK, Reis FM, Sanchez F, Romero S, Vega M, Woodruff TK. Building Oncofertility Core Competency in Developing Countries: Experience From Egypt, Tunisia, Brazil, Peru, and Panama. JCO Glob Oncol. 2020 Nov;6:360-368. doi: 10.1200/GO.22.00006. — View Citation
Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9. — View Citation
Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oocyte survival rate | The survival rate will be calculated by dividing the number of oocytes that survive freezing/thawing by the number of oocytes originally frozen.
Survival rate will be evaluated per patient, per vitrification protocol. |
6 months | |
Secondary | Oocyte maturation rate | The maturation rate will be calculated by dividing the number of oocytes that mature by the number of oocytes originally plated. | 6 months | |
Secondary | Fertilization rate | The fertilization rate will be calculated by dividing the number of fertilized oocytes by the number of oocytes injected by ICSI. | 6 months | |
Secondary | Cleavage rate | The cleavage rate will be calculated by dividing the number of cleaving embryos by the number of fertilized oocytes. | 6 months | |
Secondary | Rate of Blastocyst formation | The rate of blastocyst formation will be calculated by dividing the number of blastocysts by the number of fertilized oocytes. | 6 months | |
Secondary | Rate of Good quality blastocysts | The rate of good quality blastocysts will be calculated by dividing the number of good quality blastocysts by the number of fertilized oocytes. | 6 months | |
Secondary | Clinical pregnancy rate | The clinical pregnancy rate will be calculated by dividing the number of patients with clinical pregnancy by the number of patients that underwent embryo transfer procedures. | 15 months | |
Secondary | Live birth rate | The live birth rate will be calculated by dividing the number of patients with a live birth by the number of patients that underwent embryo transfer procedures. | 15 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT06074796 -
The Determinants of Fertility Preservation in TRANSgender Patients.
|
||
Completed |
NCT01448460 -
Oocyte Vitrification for In Vitro Fertilization (IVF) Patients and Women With Fertility Threatening Conditions
|
N/A | |
Recruiting |
NCT02400827 -
Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors
|
N/A | |
Recruiting |
NCT02400970 -
Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors
|
N/A | |
Recruiting |
NCT02895165 -
PREgnancy and FERtility Registry
|
||
Not yet recruiting |
NCT03725280 -
Micro RNA Profile in the Ovarian Follicle Fluid of Transgender Men
|
||
Recruiting |
NCT04904263 -
Advisory Board on Cancer, Infertility and Pregnancy
|
||
Not yet recruiting |
NCT06289062 -
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06289751 -
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
|
Phase 2 | |
Completed |
NCT01696786 -
Oocyte Cryopreservation
|
N/A | |
Recruiting |
NCT05372549 -
Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation
|
N/A | |
Not yet recruiting |
NCT06468215 -
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
|
N/A | |
Completed |
NCT01645241 -
Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
|
N/A | |
Completed |
NCT01160315 -
Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06175832 -
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
|
Phase 4 | |
Active, not recruiting |
NCT00827476 -
Improving Human Ovarian Transplantation
|
Phase 0 | |
Completed |
NCT00380406 -
PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial
|
Phase 3 | |
Active, not recruiting |
NCT03817814 -
Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment
|
||
Recruiting |
NCT05443737 -
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
|
Phase 3 |